Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Autolus Therapeutics (AUTL) Operating Income: 2017-2024

Historic Operating Income for Autolus Therapeutics (AUTL) over the last 8 years, with Dec 2024 value amounting to -$241.4 million.

  • Autolus Therapeutics' Operating Income fell 5.52% to -$71.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$273.9 million, marking a year-over-year decrease of 25.18%. This contributed to the annual value of -$241.4 million for FY2024, which is 34.35% down from last year.
  • Per Autolus Therapeutics' latest filing, its Operating Income stood at -$241.4 million for FY2024, which was down 34.35% from -$179.7 million recorded in FY2023.
  • Over the past 5 years, Autolus Therapeutics' Operating Income peaked at -$141.1 million during FY2021, and registered a low of -$241.4 million during FY2024.
  • In the last 3 years, Autolus Therapeutics' Operating Income had a median value of -$179.7 million in 2023 and averaged -$188.2 million.
  • In the last 5 years, Autolus Therapeutics' Operating Income grew by 16.11% in 2021 and then crashed by 34.35% in 2024.
  • Autolus Therapeutics' Operating Income (Yearly) stood at -$168.1 million in 2020, then climbed by 16.11% to -$141.1 million in 2021, then decreased by 1.67% to -$143.4 million in 2022, then fell by 25.31% to -$179.7 million in 2023, then plummeted by 34.35% to -$241.4 million in 2024.